theMednetRegister

Nuclear Medicine

ESMO 2025   

Questions discussed in this category

In light of the pending overall survival data and reported declines in quality of life associated with the PSMAddition trial, how do you envision incorporating Pluvicto into the management of mHSPC?
This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...
1 Answer available

Related Topics in Nuclear Medicine

Copyright © 2026 theMednet
All Rights Reserved.